These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 35389311)

  • 1. Cost-effectiveness of screening for atrial fibrillation in a single primary care center at a 3-year follow-up.
    Ghazal F; Aronsson M; Al-Khalili F; Rosenqvist M; Levin LÅ
    Scand Cardiovasc J; 2022 Dec; 56(1):35-41. PubMed ID: 35389311
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anticoagulation Therapy for Atrial Fibrillation in Patients With Alzheimer's Disease.
    Ruiz Vargas E; Sposato LA; Lee SAW; Hachinski V; Cipriano LE
    Stroke; 2018 Dec; 49(12):2844-2850. PubMed ID: 30571418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of screening for atrial fibrillation in primary care with a handheld, single-lead electrocardiogram device in the Netherlands.
    Jacobs MS; Kaasenbrood F; Postma MJ; van Hulst M; Tieleman RG
    Europace; 2018 Jan; 20(1):12-18. PubMed ID: 27733465
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of warfarin care bundles and novel oral anticoagulants for stroke prevention in patients with atrial fibrillation in Thailand.
    Ng SS; Nathisuwan S; Phrommintikul A; Chaiyakunapruk N
    Thromb Res; 2020 Jan; 185():63-71. PubMed ID: 31770689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of insertable cardiac monitors for the detection of atrial fibrillation in patients with cryptogenic stroke in the United States is cost-effective.
    Maervoet J; Bossers N; Borge RP; Hilpert ST; van Engen A; Smala A
    J Med Econ; 2019 Nov; 22(11):1221-1234. PubMed ID: 31480905
    [No Abstract]   [Full Text] [Related]  

  • 6. Cost-effectiveness of clopidogrel plus aspirin for stroke prevention in patients with atrial fibrillation in whom warfarin is unsuitable.
    Coleman CI; Straznitskas AD; Sobieraj DM; Kluger J; Anglade MW
    Am J Cardiol; 2012 Apr; 109(7):1020-5. PubMed ID: 22221944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atrial Fibrillation Screen, Management, and Guideline-Recommended Therapy in the Rural Primary Care Setting: A Cross-Sectional Study and Cost-Effectiveness Analysis of eHealth Tools to Support All Stages of Screening.
    Orchard J; Li J; Freedman B; Webster R; Salkeld G; Hespe C; Gallagher R; Patel A; Kamel B; Neubeck L; Lowres N
    J Am Heart Assoc; 2020 Sep; 9(18):e017080. PubMed ID: 32865129
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of population screening for atrial fibrillation: the STROKESTOP study.
    Lyth J; Svennberg E; Bernfort L; Aronsson M; Frykman V; Al-Khalili F; Friberg L; Rosenqvist M; Engdahl J; Levin LÅ
    Eur Heart J; 2023 Jan; 44(3):196-204. PubMed ID: 36349968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomised controlled trial and cost-effectiveness study of systematic screening (targeted and total population screening) versus routine practice for the detection of atrial fibrillation in people aged 65 and over. The SAFE study.
    Hobbs FD; Fitzmaurice DA; Mant J; Murray E; Jowett S; Bryan S; Raftery J; Davies M; Lip G
    Health Technol Assess; 2005 Oct; 9(40):iii-iv, ix-x, 1-74. PubMed ID: 16202350
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Feasibility and cost-effectiveness of stroke prevention through community screening for atrial fibrillation using iPhone ECG in pharmacies. The SEARCH-AF study.
    Lowres N; Neubeck L; Salkeld G; Krass I; McLachlan AJ; Redfern J; Bennett AA; Briffa T; Bauman A; Martinez C; Wallenhorst C; Lau JK; Brieger DB; Sy RW; Freedman SB
    Thromb Haemost; 2014 Jun; 111(6):1167-76. PubMed ID: 24687081
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-Effectiveness Analysis of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation in Taiwan.
    Liu CY; Chen HC
    Clin Drug Investig; 2017 Mar; 37(3):285-293. PubMed ID: 27988835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of screening for paroxysmal atrial fibrillation in patients undergoing echocardiography.
    Ramkumar S; Kawakami H; Wong E; Nolan M; Marwick TH
    Intern Med J; 2023 May; 53(5):760-772. PubMed ID: 35377542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of apixaban compared to warfarin in the management of atrial fibrillation in Australia.
    Ademi Z; Pasupathi K; Liew D
    Eur J Prev Cardiol; 2015 Mar; 22(3):344-53. PubMed ID: 24281250
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of rivaroxaban compared to warfarin for stroke prevention in atrial fibrillation.
    Lee S; Anglade MW; Pham D; Pisacane R; Kluger J; Coleman CI
    Am J Cardiol; 2012 Sep; 110(6):845-51. PubMed ID: 22651881
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral anticoagulants for primary prevention, treatment and secondary prevention of venous thromboembolic disease, and for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis and cost-effectiveness analysis.
    Sterne JA; Bodalia PN; Bryden PA; Davies PA; López-López JA; Okoli GN; Thom HH; Caldwell DM; Dias S; Eaton D; Higgins JP; Hollingworth W; Salisbury C; Savović J; Sofat R; Stephens-Boal A; Welton NJ; Hingorani AD
    Health Technol Assess; 2017 Mar; 21(9):1-386. PubMed ID: 28279251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of a community-based screening programme for chronic atrial fibrillation in Japan.
    Maeda K; Shimbo T; Fukui T
    J Med Screen; 2004; 11(2):97-102. PubMed ID: 15153326
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of apixaban compared with aspirin for stroke prevention in atrial fibrillation among patients unsuitable for warfarin.
    Lee S; Anglade MW; Meng J; Hagstrom K; Kluger J; Coleman CI
    Circ Cardiovasc Qual Outcomes; 2012 Jul; 5(4):472-9. PubMed ID: 22740012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of Dabigatran Compared With Rivaroxaban for Prevention of Stroke and Systemic Embolism in Patients With Atrial Fibrillation in China.
    Dong SJ; Wu B; Zhai SD; Zhang YJ; Chu YB; Gupta P; Li YH
    Clin Ther; 2020 Jan; 42(1):144-156.e1. PubMed ID: 31932080
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with atrial fibrillation at high risk of bleeding and normal kidney function.
    Hernandez I; Smith KJ; Zhang Y
    Thromb Res; 2017 Feb; 150():123-130. PubMed ID: 27771008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost effectiveness of rivaroxaban for stroke prevention in German patients with atrial fibrillation.
    Mensch A; Stock S; Stollenwerk B; Müller D
    Pharmacoeconomics; 2015 Mar; 33(3):271-83. PubMed ID: 25404426
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.